News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
348,435 Results
Type
Article (21201)
Company Profile (142)
Press Release (327078)
Multimedia
Podcasts (112)
Webinars (17)
Section
Business (106564)
Career Advice (891)
Deals (18857)
Drug Delivery (110)
Drug Development (51346)
Employer Resources (80)
FDA (7898)
Job Trends (7839)
News (188135)
Policy (17585)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (748)
Accelerated approval (19)
Adcomms (23)
Allergies (83)
Alliances (28162)
ALS (90)
Alzheimer's disease (794)
Antibody-drug conjugate (ADC) (207)
Approvals (8079)
Artificial intelligence (283)
Autoimmune disease (81)
Automation (15)
Bankruptcy (180)
Best Places to Work (5563)
BIOSECURE Act (14)
Biosimilars (170)
Biotechnology (61)
Bladder cancer (74)
Brain cancer (34)
Breast cancer (264)
Cancer (2313)
Cardiovascular disease (241)
Career advice (740)
Career pathing (24)
CAR-T (110)
CDC (14)
Cell therapy (287)
Cervical cancer (11)
Clinical research (45050)
Collaboration (1016)
Company closure (1)
Compensation (374)
Complete response letters (52)
COVID-19 (1163)
CRISPR (49)
C-suite (533)
Cystic fibrosis (89)
Data (3315)
Decentralized trials (2)
Denatured (27)
Depression (83)
Diabetes (249)
Diagnostics (1936)
Digital health (15)
Diversity (9)
Diversity, equity & inclusion (22)
Drug discovery (171)
Drug pricing (200)
Drug shortages (33)
Duchenne muscular dystrophy (138)
Earnings (41229)
Editorial (46)
Employer branding (10)
Employer resources (78)
Events (51316)
Executive appointments (620)
FDA (9496)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (3)
Frontotemporal dementia (5)
Funding (665)
Gene editing (90)
Generative AI (31)
Gene therapy (269)
GLP-1 (824)
Government (2034)
Grass and pollen (5)
Guidances (211)
Healthcare (6004)
HIV (28)
Huntington's disease (24)
IgA nephropathy (61)
Immunology and inflammation (169)
Immuno-oncology (35)
Indications (70)
Infectious disease (1302)
Inflammatory bowel disease (120)
Inflation Reduction Act (12)
Influenza (46)
Intellectual property (136)
Interviews (118)
IPO (7542)
IRA (53)
Job creations (2448)
Job search strategy (653)
JPM (52)
Kidney cancer (10)
Labor market (61)
Layoffs (344)
Leadership (27)
Legal (4171)
Liver cancer (37)
Longevity (8)
Lung cancer (333)
Lymphoma (208)
Machine learning (21)
Management (31)
Manufacturing (529)
MASH (104)
Medical device (2060)
Medtech (2068)
Mergers & acquisitions (11842)
Metabolic disorders (885)
Multiple sclerosis (104)
NASH (20)
Neurodegenerative disease (161)
Neuropsychiatric disorders (71)
Neuroscience (1524)
Neurotech (1)
NextGen: Class of 2026 (2366)
Non-profit (918)
Now hiring (45)
Obesity (517)
Opinion (232)
Ovarian cancer (66)
Pain (147)
Pancreatic cancer (95)
Parkinson's disease (155)
Partnered (18)
Patents (280)
Patient recruitment (245)
Peanut (19)
People (34606)
Pharmaceutical (76)
Pharmacy benefit managers (33)
Phase 1 (14175)
Phase 2 (19030)
Phase 3 (15264)
Pipeline (2912)
Policy (235)
Postmarket research (1624)
Preclinical (4968)
Press Release (29)
Prostate cancer (132)
Psychedelics (27)
Radiopharmaceuticals (182)
Rare diseases (526)
Real estate (3215)
Recruiting (33)
Regulatory (13864)
Reports (25)
Research institute (841)
Resumes & cover letters (140)
Rett syndrome (6)
RNA editing (12)
RSV (43)
Schizophrenia (118)
Series A (120)
Series B (83)
Service/supplier (7)
Sickle cell disease (65)
Special edition (21)
Spinal muscular atrophy (119)
Sponsored (18)
Startups (2049)
State (2)
Stomach cancer (12)
Supply chain (77)
Tariffs (94)
The Weekly (83)
Vaccines (449)
Venture capital (68)
Weight loss (378)
Women's health (40)
Worklife (9)
Date
Today (35)
Last 7 days (263)
Last 30 days (1041)
Last 365 days (15355)
2026 (1505)
2025 (15578)
2024 (17817)
2023 (19787)
2022 (26073)
2021 (26981)
2020 (25078)
2019 (20214)
2018 (15682)
2017 (17395)
2016 (16335)
2015 (18906)
2014 (14899)
2013 (12693)
2012 (13601)
2011 (13918)
2010 (12858)
Location
Africa (420)
Alabama (41)
Alaska (1)
Arizona (93)
Arkansas (8)
Asia (25984)
Australia (3351)
California (4813)
Canada (1826)
China (749)
Colorado (196)
Connecticut (195)
Delaware (180)
Europe (54818)
Florida (833)
Georgia (97)
Hawaii (2)
Idaho (18)
Illinois (441)
India (51)
Indiana (294)
Iowa (5)
Japan (323)
Kansas (83)
Kentucky (29)
Louisiana (7)
Maine (4)
Maryland (602)
Massachusetts (3870)
Michigan (68)
Minnesota (241)
Mississippi (3)
Missouri (42)
Montana (12)
Nebraska (14)
Nevada (35)
New Hampshire (10)
New Jersey (1855)
New Mexico (21)
New York (1312)
North Carolina (797)
North Dakota (2)
Northern California (2254)
Ohio (130)
Oklahoma (8)
Oregon (23)
Pennsylvania (1060)
Puerto Rico (19)
Rhode Island (27)
South America (618)
South Carolina (12)
Southern California (2035)
Tennessee (64)
Texas (656)
United States (18210)
Utah (94)
Virginia (177)
Washington D.C. (60)
Washington State (375)
West Virginia (1)
Wisconsin (49)
Wyoming (1)
348,435 Results for "nordic pharma amring pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Amring Pharmaceuticals Inc. Announces Name Change to Nordic Pharma, Inc. Under New Nordic Group, B.V. Ownership
Amring Pharmaceuticals Inc. (“Amring”) announces its name change to Nordic Pharma, Inc. on March 4, 2024, following the change in ownership of the company from SEVER Life Sciences, B.V. to Nordic Group, B.V., a subsidiary of SEVER Life Sciences B.V., which occurred on June 1, 2023.
March 4, 2024
·
3 min read
Press Releases
CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR)
January 16, 2026
·
7 min read
Deals
Nordic Pharma Group B.V. Through Its Subsidiary Amring Pharmaceuticals Inc., Completes Acquisition of Visant Medical to Launch Novel Therapy for Dry Eye Disease in the United States
Amring Pharmaceuticals Inc. (Amring), a subsidiary of Nordic Group B.V. (Nordic Pharma), announced today the completion of its acquisition of Visant Medical, Inc. (Visant), a leader in medical technology innovation in Dry Eye Disease (DED).
December 18, 2023
·
5 min read
Press Releases
NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), TO SHARE PATIENT DATA AND PATIENT EXPERIENCE STUDY FOR LACRIFILL® CANALICULAR GEL, A NOVEL THERAPY FOR DRY EYE, DURING AMERICAN ACADEMY OF OPHTHALMOLOGY (AAO) 2025
October 17, 2025
·
4 min read
Press Releases
Bavarian Nordic Signs Distribution Agreement with Eurofarma to Expand Access to Chikungunya Vaccine in Brazil
January 26, 2026
·
5 min read
Press Releases
Heidi Hunter Appointed New Vice Chair of the Board of Directors of Bavarian Nordic
December 17, 2025
·
1 min read
Press Releases
Vicore to Present at the DNB Carnegie Nordic Healthcare Conference
November 20, 2025
·
1 min read
Business
Nordic Group B.V. Through Its Subsidiary Amring Pharmaceuticals Inc., Announces Jai G. Parekh, MD, MBA as Chief Commercial Officer, Eye Care U.S.
Amring Pharmaceuticals Inc., a subsidiary of Nordic Group B.V., announces Jai G. Parekh, MD, MBA as Chief Commercial Officer, Eye Care U.S. Nordic Pharma recently expanded its pharmaceutical expertise in the U.S. by acquiring Visant Medical, Inc., a leader in medical technology innovation in Dry Eye Disease.
January 15, 2024
·
6 min read
Press Releases
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program - February 2, 2026
February 2, 2026
·
2 min read
Press Releases
Bavarian Nordic Launches Planned Share Buy-Back Program
January 7, 2026
·
2 min read
1 of 34,844
Next
